TETAF | HHS Calls on Center for Innovation to Accelerate Zika Vaccine Development
17279
post-template-default,single,single-post,postid-17279,single-format-standard,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-10.1.1,wpb-js-composer js-comp-ver-5.0.1,vc_responsive

HHS Calls on Center for Innovation to Accelerate Zika Vaccine Development

27 Jun

HHS Calls on Center for Innovation to Accelerate Zika Vaccine Development

To accelerate development of a Zika vaccine, the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) will begin developing a vaccine using its Center for Innovation in Advanced Development and Manufacturing (CIADM) in Baltimore, Maryland.

With funding and direction from ASPR’s Biomedical Advanced Research and Development Authority (BARDA), the CIADM led by Emergent BioSolutions, Inc., will conduct a variety of studies to move quickly through early stages of vaccine development and submit an investigational new drug request to FDA to begin clinical studies. To further speed development time, the CIADM will use vaccine technology similar to that used in vaccines being developed to protect against similar viruses, such as Dengue.

Read more about today’s announcement.



X